4-butoxy-2-fluorobromobenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-butoxy-2-fluorobromobenzene
• 英文别名: 1-bromo-4-butoxy-2-fluorobenzene
• 化学式: C₁₀H₁₂BrFO
• 分子量: 247.107
• InChiKey: QQZQZZKHAQDOQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-乙烯基吡啶 、 4-butoxy-2-fluorobromobenzene 在 palladium diacetate 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 乙腈 为溶剂， 反应 72.0h， 生成 4-[(E)-2-(4-Butoxy-2-fluoro-phenyl)-vinyl]-pyridine
  参考文献：
  名称：

  Mesomorphic Metal Complexes Derived from 4-Alkyl-oxystilbazoles

  摘要：

  DOI：

  10.1080/10587259208038507

文献信息

• LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA
  申请人：JANSEN Axel

  公开号：US20110253935A1

  公开（公告）日：2011-10-20

  The present invention relates to liquid-crystalline compounds having two fluorinated biphenyl units, a terminal trifluoromethyl or trifluoromethoxy group and a —CF 2 O— bridge between the two fluorinated biphenyl units. The invention also relates to liquid-crystalline media prepared therewith and to liquid-crystal display devices (LC displays) containing these media.

  本发明涉及具有两个氟代联苯单元、末端三氟甲基或三氟甲氧基基团以及两个氟代联苯单元之间的—CF2O—桥的液晶化合物。本发明还涉及使用这些化合物制备的液晶介质以及包含这些介质的液晶显示器件（LC显示器）。
• New pharmaceutical combinations for NOS inhibitors
  申请人：Pfizer Inc

  公开号：US20040229911A1

  公开（公告）日：2004-11-18

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药物用途。具体地，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一种活性剂联合使用，特别是SSRI或NK-1受体拮抗剂，用于治疗可以通过改变昼夜节律来达到或促进治疗的疾病或病况。这些疾病和病况的例子包括失明、肥胖症、季节性情感障碍、双相情感障碍、时差反应、昼夜节律睡眠障碍、睡眠剥夺、睡眠障碍、REM睡眠障碍、嗜睡症、睡眠-觉醒周期障碍、嗜睡症和与轮班工作或不规则工作时间表相关的睡眠障碍、夜尿症和不宁腿综合症。
• Liquid-crystalline compounds and liquid-crystalline media
  申请人：Jansen Axel

  公开号：US08551359B2

  公开（公告）日：2013-10-08

  The present invention relates to liquid-crystalline compounds having two fluorinated biphenyl units, a terminal trifluoromethyl or trifluoromethoxy group and a —CF2O— bridge between the two fluorinated biphenyl units. The invention also relates to liquid-crystalline media prepared therewith and to liquid-crystal display devices (LC displays) containing these media.

  本发明涉及具有两个氟化联苯单元，末端三氟甲基或三氟甲氧基和在两个氟化联苯单元之间具有—CF2O—桥的液晶化合物。本发明还涉及使用这些化合物制备的液晶介质以及包含这些介质的液晶显示器件(LC显示器)。
• LIQUID CRYSTAL COMPOUND HAVING CF2O BONDING GROUP AND TOLANE BACKBONE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT
  申请人：JNC Corporation

  公开号：EP3156388A1

  公开（公告）日：2017-04-19

  To provide a liquid crystal compound satisfying at least one of physical properties such as high chemical stability, a high clearing point, a low minimum temperature of a liquid crystal phase, low viscosity, large optical anisotropy, large dielectric anisotropy, a suitable elastic constant and excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. A compound is represented by formula (1). In formula (1), for example, R1 is alkyl having 1 to 15 carbons; ring A1, ring A2 and ring A3 are independently 1,4-phenylene, 2-halogeno-1,4-phenylene or 2,6-dihalogeno-1,4-phenylene; Z1 and Z2 are independently a single bond or -C≡C-, but at least one is -C≡C-; L1 is halogen, -OCF3 or -CF3; L2 and L3 are independently hydrogen or halogen, but at least one is halogen; and m and n are independently 0, 1 or 2, and a sum of m and n is 1 or 2.

  目的：提供一种液晶化合物，该化合物至少满足以下物理特性中的一项：化学稳定性高、清澈点高、液晶相最低温度低、粘度低、光学各向异性大、介电各向异性大、弹性常数合适以及与其他液晶化合物的兼容性好；提供一种含有该化合物的液晶组合物和一种包括该组合物的液晶显示设备。 一种化合物用式（1）表示。 例如，在式 (1) 中，R1 是具有 1 至 15 个碳原子的烷基；环 A1、环 A2 和环 A3 独立地是 1,4-亚苯基、2-卤代-1,4-亚苯基或 2,6-二卤代-1,4-亚苯基；Z1 和 Z2 独立地为单键或-C≡C-，但至少有一个为-C≡C-；L1 为卤素、-OCF3 或-CF3；L2 和 L3 独立地为氢或卤素，但至少有一个为卤素；以及 m 和 n 独立地为 0、1 或 2，m 和 n 之和为 1 或 2。
• Removal of Sphingosine 1-Phosphate Receptor-3 (S1P₃) Agonism is Essential, But Inadequate to Obtain Immunomodulating 2-Aminopropane-1,3-diol S1P₁ Agonists with Reduced Effect on Heart Rate
  作者：Maiko Hamada、Mitsuharu Nakamura、Masatoshi Kiuchi、Kaoru Marukawa、Ayumi Tomatsu、Kyoko Shimano、Noriko Sato、Kunio Sugahara、Mahoko Asayama、Kan Takagi、Kunitomo Adachi

  DOI：10.1021/jm901776q

  日期：2010.4.22

  A series of 2-substituted 2-aminopropane-1,3-diols having a biphenyl moiety and their phosphate esters were synthesized to obtain sphingosine 1-phosphate receptor-1 (S1P(1)) receptor agonists with potent immunomodulatory activity accompanied by little or no effect on heart rate. Many of the synthesized compounds sufficiently decreased the number of peripheral blood lymphocytes. Some of the phosphates had potent agonism at S1P(1) but no agonism at S1P(3), which had been reported to be a receptor responsible for heart rate reduction. Although high S1P(1)/S1P(3) selectivity was considered to be favorable to reduce the effect on heart rate, almost all the phosphates showed a remarkable heart rate lowering effect in vivo. The results suggest that other factors in addition to S1P(3) agonism should be responsible for the heart rate reduction caused by S1P(1) agonists. Only 2-amino-2-[2-[2'-fluoro-4'-(4-methylphenylthio)biphenyl-4-yl]ethyl]propane-1,3-diol (6d) was identified as a desired S1P(1) receptor agonist having both the immunomodulatory activity and an attenuated effect on heart rate by a unique screening flow using in vivo evaluating systems primarily.